These studies help to understand that CFTR modulator is safe in younger ages and leads to improved outcomes compared to later age of initiation; however, as use in young ages is still relatively new, the effect on more long‐term outcomes such as CF‐related diabetes or CF hepatobiliary disease has yet to be seen. This evidence concerns the gene CFTR and cystic fibrosis.